A number of humoral mediators, including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), have been implicated in angiogenesis. 5, 6) During tissue neovascularization, adhesive interactions of endothelial cells with the extracellular matrix (ECM) play a critical role in the key processes of angiogenesis. 7) Thus, in addition to humoral factors, cell adhesion receptors also act as angiogenic factors.
Cell adhesion to ECM proteins is mainly mediated by the b1-and b3-subfamilies of integrins. 8) The most unique and physiologically important feature of b1 integrins is their ability to alter their ligand-binding and signaling activities. These integrins can alter their ability to adhere to ECM proteins in response to extracellular stimuli and, thus are able to vary signal transduction for the regulation of fundamental cellular processes, such as proliferation, migration, differentiation and gene expression. 9) In this sense, angiogenesis is under the control of integrin function. Accordingly, the targeting of integrins is postulated to have potential therapeutic relevance in angiogenic disorders.
We previously found that fibronectin (FN), a typical adhesive ECM protein, harbors a cryptic functional site opposing cell adhesion to the ECM. 10) FNIII14, a 22-mer FN peptide that contains this active site, inhibits cell adhesion to the ECM by inactivating b1-integrins. 11, 12) Interestingly, tenascin (TN)-C, which is an antiadhesive ECM protein, has a cryptic functional site that stimulates cell adhesion to the ECM. 13 ) A 22-mer TN-C peptide containing this cryptic site, termed TNIIIA2, positively regulates b1-integrin-mediated cell adhesion to the ECM by inducing a conformational change in b1-integrins, which is necessary for their functional activation. 13) These cryptic sites appear to become functionally exposed by processing the FN and TN-C molecules with matrix metalloproteinase-2 (MMP-2). 13, 14) It may be expected that modulation of b1-integrin function contributes to modulation of cellular processes, such as cell proliferation and migration. These integrin function regulatory peptides, FNIII14 and TNIIIA2, may be useful for control of angiogenesis.
We have investigated the effect of TNIIIA2 on angiogenic cellular processes. First, TNIIIA2 was shown to activate b1-integrins on vascular endothelial cells. Next, TNIIIA2 inhibited migration and proliferation of human dermal microvascular endothelial cells (HDMEC), in concomitant with reduced activation of Rac, a Rho family GTPase involved in integrin-dependent cell migration, and MAP-kinase (ERK1/2), a signaling molecule essential for cell proliferation. Moreover, we show antiangiogenic effect of TNIIIA2 by the chorioallantoic membrane (CAM) assay, an in vivo method for the study of angiogenesis. Thus, TNIIIA2 may have the ability to inhibit angiogenesis by negatively regulating cell motility and growth. 
Inhibition of Angiogenesis by a Tenascin

MATERIALS AND METHODS
Materials
Peptide TNIIIA2 and its inactive control peptide, TNIIImut, whose 18th Ileu is exchanged by Ala, 13) were purchased from Operon. Function-blocking monoclonal antibodies (mAbs) against integrin subunits a4 (P1H4) and a5 (P1D6) were purchased from CHEMICON, while that against human integrin subunit b1 (DE9) was from UPSTATE. mAb recognizing the active conformation of integrin subunit b1 AG89 was purchased from MBL.
Cell Culture HDMEC, obtained from Sanko Lab (Tokyo), were grown on gelatin-coated plates in MCDB105 medium supplemented with 15% fetal bovine serum (FBS) and endothelial cell growth medium (EGM2-MV) (Sanko Lab, Tokyo) (growth medium).
Cell Proliferation HDMEC were seeded on a 96-well plate coated with FN and cultured for 4 h. Cells were then cultured with fresh medium in the presence or absence of TNIIIA2 for 24 h. The number of viable cells was evaluated based on the conventional MTT assay using Cell Counting kit (DOJINDO, Tokyo, Japan) according to the manufacturer's instructions as described previously.
15)
Cell Cycle Analysis HDMEC were cultured in the growth medium with or without TNIIIA2 for 48 h. Cells harvested were incubated with the bromodeoxyuridine (BrdU) Flow Kit (BD Biosciences), fixed, permeabilized and then stained with fluorochrome-conjugated anti-BrdU. The cells were then incubated with 7-amino-actinomycin D to stain the DNA, and flow cytometric analysis was performed (BD, Cell Quest software).
Flow Cytometric Analysis Activation of b1 integrins on the cells was evaluated by flow cytometric analysis using AG89 (MBL), which recognizes the active b1 integrin conformation-specific epitope, 16) as described previously.
13,14)
Wound Scratch Assay HDMEC were grown on a 12-well plate coated with FN (1 mg/ml) until confluent. A straight line was drawn with a marker on the outer surface of the plate bottom. An artificial wound was made in the confluent monolayer of HDMEC at a right angle, by using a pipet tip. The plate was rinsed 3-times and then incubated with the growth medium in the presence of indicated concentration of TNIIIA2 or TNIIIA2 in combination with FNIII14, as indicated. After a 6-h incubation, distances of the empty space at either side of the marker line were measured. Cell migration was assessed in accordance with the Migration Index.
17)
Rac Activity Assay HDMEC (3ϫ10 5 cells/well) were incubated on FN-coated plate in the growth medium with or without TNIIIA2 (40 mg/ml) for different times. Rac activity assay was performed using Rac pull-down assay kit (Cell signaling technology) according to the manufacturer's instructions. GTP-binding/activated forms of Rac were visualized by immunoblot analysis using anti-Rac antibody. All biochemical and immunoblotting assays were repeated at least thrice.
Western Blot Analysis Cells (3ϫ10 5 cells/well) were incubated on FN-coated plate in the growth medium with or without TNIIIA2 for different times. Cells were dissolved with the SDS sample buffer and subjected to immunoblot analysis using anti-ERL1/2 (Cell Signaling Technology), and anti-ERK1/2 (Cell Signaling Technology) or anti-focal adhesion kinase (FAK) (pY397) (Biosource International, Inc.), as described previously. 18) Immunoprecipitation Cells (3ϫ10 5 cells/well) were serum-starved for 5 h and then incubated with or without TNIIIA2 (40 mg/ml) for different times. Cells were dissolved with Lysis buffer (10 mM Tris-HCl buffer, pH 7.4, containing 0.15 M NaCl, 1% NP-40 and 2 mM PMSF) and immunoprecipitated with anti-FAK antibody. The immunoprecipitated proteins were analysis by SDS-PAGE, followed by immunoblotting using anti-paxillin (pY118) 19) Ab. Chick Embryo Chorioallantoic Membrane (CAM) Assay In vivo angiogenic activity was assayed using CAMs as described previously. 20) TNIIIA2 was mixed in 1% methyl cellulose/0.9% NaCl. On day 4 of the fertilized chick embryo in a shell, 10 ml of TNIIIA2 preparation was applied to the silicon ring that was placed on the surface of the CAM. After 48 h exposure at 37°C, the fat emulsion was injected into CAM to visualize the blood vessels. Angiogenic inhibition was indicated by the formation of an avascular zone around the ring of 3 mm diameter. The results were expressed as the ratio of the number of eggs with neovascularity to the total number of eggs tested.
RESULTS
Effect of TNIIIA2-Treatment on HDMEC Migration and Proliferation on the FN Substrate
First of all, we examined whether TNIIIA2 was able to induce activation of b1-integrins on HDMEC. The status of b1 integrin activation can be evaluated by its accessibility to an anti-b1 integrin mAb, such as AG89, which recognizes the active conformation-specific epitope of the b1 subunit, regardless of the a subunit. 16) Similar to the effects on b1-integrins of fibroblastic cells, 13) TNIIIA2, but not its control peptide TNIIIA2mut (see Materials and Methods), induced expression of the AG89 epitope on HDMEC in a dose-dependent manner (Figs. 1A-D) . b1-Integrin activation by TNIIIA2 was reversed ( Fig. 1E) when FNIII14 , an antiadhesive peptide derived from FN, that has the ability to inactivate b1-integrins (see above), 12) was used in combination with TNIIIA2. Thus, TNIIIA2 was demonstrated to induce activation of b1-integrins on HDMEC.
Based on these results, the effects of b1-integrin activation on HDMEC migration and proliferation, as key processes for angiogenesis, were investigated. This experiment was carried out on a culture plate coated with FN, which is a predominant ECM protein in the interstitial tissues, because vascular endothelial cells interact with an FN-rich interstitial environment during the invasion phase of angiogenesis.
Haptotactic migration of HDMEC was assessed by an in vitro wound scratch assay. The confluent monolayers of HDMEC scratched with a linear wound were incubated for 6 h with the growth medium in the presence or absence of increased concentrations of TNIIIA2. TNIIIA2, but not TNIIImut, inhibited migration of HDMEC on the FN substrate into the scratches (Fig. 2A) . Inhibition of HDMEC migration was dependent on TNIIIA2 concentration, in which motility in the presence of TNIII (40 mg/ml) was less than 40% of that without the peptide (Fig. 2A) . FNIII14, an FN peptide opposing b1-integrin activation, 12) had no significant effect on HDMEC migration by itself (data not shown), but was capable of restoring HDMEC migration when used in combi-nation with TNIIIA2 (Fig. 2B) . Since cell adhesion assay using the function-blocking anti-integrin antibodies and RGD peptide revealed that HDMEC adhered to the FN mainly via a5b1 (Fig. 2C) , we next examined the effect of TNIIIA2 on the activation status of FAK and Rac GTPase, both of which are involved in the integrin-mediated cell migration. 21) As shown in Fig. 2D , autophosphorylation of FAK (Tyr 397) was no longer unchanged when HDMEC previously adhered to the FN substrate were stimulated with TNI-IIA2, whereas a physical association of FAK with phosphopaxillin (Tyr 118) became evident. Simultaneously, Rac activation was inhibited remarkably by the TNIIIA2-treatment, suggesting the involvement of FAK/phospho-paxillin in the TNIIIA2-induced Rac inactivation and resulting decreased cell motility. 22, 23) TNIIIA2 expressed no significant cytotoxic effect on HDMEC, at least under the conditions of this assay (data not shown).
We next examined the effect of TNIIIA2 on HDMEC proliferation on the FN substrate. HDMEC, which had spread on the FN substrate, were cultured with the growth medium in the presence or absence of TNIIIA2. After a day of culture, the number of viable cells increased by about 2-fold in the absence of TNIIIA2 (Fig. 3A-a) . TNIIIA2, not TNIIImut, inhibited this proliferation in a dose-dependent manner (Fig.  3A-a) , whereas further addition of FNIII14 restored HDMEC proliferation to the control level (Fig. 3A-b) . Moreover, cell cycle analysis of HDMEC labeled with BrdU and 7-aminoactinomycin D was performed. After stimulation with TNI-IIA2, there was only a small increase in the population of sub-G 1 cells (from 3.9 to 6.4%), whereas the population of G 0 /G 1 cells increased from 69 to 78% and, conversely, the population of S and G 2 /M cells decreased from 27 to 15.5% (Fig. 3B) . The results suggested that the inhibition of HDMEC proliferation might be mainly due to growth arrest at G 0 /G 1 phase without a marked decrease in cell viability (Fig. 3B) . To define further the inhibitory effect of TNIIIA2 HDMEC suspended in the growth medium were incubated with vehicle (A), TNIIIA2 (10 mg/ml) (B), TNIIIA2 (50 mg/ml) (C), TNIIImut (50 mg/ml) (D), or TNIIIA2 (50 mg/ml) plus FNIII14 (100 mg/ml) (E) for 30 min. Flow cytometric analysis was performed using the FITC-labeled anti-b1 integrin mAb, AG89, as described in Materials and Methods. Data shown are representative of two individual experiments.
Fig. 2. Inhibition of HDMEC Migration on the FN Substrate by TNIIIA2
The confluent monolayers of HDMEC with a scratched linear wound were incubated with the growth medium with or without peptide. After a 6 h incubation, HDMEC migration was assessed and represented as Migration Index, 17) as described in Materials and Methods. . After a 90 min-incubation, the number of cells adhered on the FN substrate was counted as described previously. 14) Each point represents the meanϮS.E. of triplicate determinations. One of three individual experiments is shown. (D) Western blot analysis of TNIIIA2-induced intracellular signaling involved in cell migration. Upper panel: HDMEC were cultured on FN-coated plate in the absence or presence of TNIIIA2 (40 mg/ml) for the indicated times. Phosphorylation/activation of FAK was analyzed using anti-FAK (pY397). Middle panel: HDMEC incubated with or without TNIIIA2 were dissolved with Lysis buffer and subjected to immunoprecipitation using anti-FAK antibody. The precipitates were analyzed using anti-paxillin (pY118) antibody. Lower panel: HDMEC were incubated on FN-coated plate in the growth medium with or without TNIIIA2 (40 mg/ml) for the indicated times. Cells were rapidly collected, lysed and subjected to Rac pull-down assay followed by immunoblotting with anti-Rac antibody as described in Materials and Methods. Data shown are representative of two individual experiments.
on HDMEC proliferation in terms of intracellular signaling, we examined the activation status of classical MAP-kinase (ERK1/2). The data clearly showed that TNIIIA2 reduced the phosphorylated/activated forms of ERK1/2 (Fig. 3C) . Together with the above results, TNIIIA2 was shown to have the ability to inhibit both migration and proliferation of vascular endothelial cells, thus affecting the key processes of angiogenesis.
Inhibition of Chick CAM Angiogenesis by TNIIIA2 Since in vitro studies using HDMEC suggested that TNIIIA2 may be capable of inhibiting angiogenesis, we tested an in vivo effect of TNIIIA2 on angiogenesis, using the CAM assay. In the control CAMs, a developed orderly arrangement of the vessels with ladder-like interdigitation was evident ( Fig. 4A-a) . In contrast, the instillation of TNIIIA2 (5 mg) to the CAM led to significant inhibition of neovascularization in the ring (Fig. 4A-b) . In many eggs, complete prevention of neovascularization was observed in CAMs instilled with 50 mg of TNIIIA2 (Fig. 4B) .
DISCUSSION
The present study showed that TNIIIA2 has the ability to inhibit angiogenesis, as judged by the CAM assay. Since TNIIIA2 inhibited haptotactic migration and proliferation of HDMEC and since these cellular processes play critical roles in neovascularization, the antiangiogenic activity of TNIIIA2 may be due to inhibition of these cellular processes. However, the molecular mechanism by which TNIIIA2 inhibited HDMEC migration and proliferation remains to be clarified. Importantly, these inhibitions by TNIIIA2 were abrogated by FNIII14, which is capable of opposing b1-integrin activation. 12) Inhibition of HDMEC migration and proliferation may be due to b1-integrin activation by TNIIIA2, although it cannot be excluded the possibility that an additional mechanism(s) aside from b1-integrin activation may play a role.
It has been established that engagement of integrin with the ECM protein induces to activate Rac activity, leading to enhanced cell motility. 24) A variety of signaling molecules, such as FAK, Src, paxillin, p130cas and Crk, are involved in cell migration process. 25, 26) New insight proposed by Yano et al. suggest that FAK/p130cas stimulates Rac activation, whereas FAK/paxillin may inhibit Rac activity. 22, 23, 27) That is, FAK can function in inhibiting cell motility in addition to its established function in promoting migration, and FAK and paxillin function in crosstalk between cell-matrix and cell-cell adhesions. 27) In our results, TNIIIA2 reduced Rac activity, simultaneously induced a physical association of FAK with phospho-paxillin, without any change in the autophosphorylation of FAK. Tyrosine phosphorylation of paxillin at Tyr 31 and 118 are reportedly involved in opposing effects of paxillin on cell migration. 22) Future study should be performed to define a signaling pathway from integrin to paxillin phosphorylation.
On the other hand, TNIIIA2 led HDMEC to the G 0 /G 1 arrest, in concomitant with the reduced phosphorylation/activation of MAP-kinase (ERK1/2). A number of studies have demonstrated that integrin-mediated adhesion to FN causes activation of MAP-kinase (ERK1/2). 28, 29) On the contrary, there have also been some reports showing inactivation of them in different cellular contexts. [30] [31] [32] It is quite interesting that the same regulatory molecule, such as FAK as mentioned above and integrin, could positively and negatively control cellular processes, such as cell proliferation and migration.
23) It should be noted that TNIIIA2 had the ability to induce b1-integrin activation much more strongly than the usual integrin activators, such as Mn 2ϩ /Mg 2ϩ and b1-integrin-activating mAbs. 13) Hyper-activation of b1-integrins may cause generating unexpected cellular responses. With regard to cell proliferation, forced adhesion to the ECM stimulated by the high potency of integrin activation may trigger some signaling pathway leading the MAP-kinase (ERK1/2) to inactivation, like a feedback down-regulation of MAPkinase by signaling molecules, including Sprouty and Spread. [33] [34] [35] In any case, further study is needed to clarify the signaling mechanism for proliferation inhibition by TNIIIA2.
